The Stock Of The Week: Xenon Pharmaceuticals Inc. (XENE)


As of Wednesday close, Xenon Pharmaceuticals Inc.’s (NASDAQ:XENE) stock was down -$0.32, moving down -0.92 percent to $34.37. The average number of shares traded per day over the past five days has been 296,920 shares. 3 times new highs have been achieved over the past 5 days, with a $1.31 gain in that time frame. In the last twenty days, the average volume was 397,780, while in the previous 50 days, it was 351,078.

Since last month, XENE stock retreated -6.14%. Shares of the company fell to $31.79 on 11/09/22, the lowest level in the past month. A 52-week high of $41.39 was reached on 08/11/22 after having rallying from a 52-week low of $23.26. Since the beginning of this year, XENE’s stock price has risen by 10.02% or $3.13, and marked a new high 11 times. However, the stock has declined by -16.96% since its 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


XENE stock investors should be aware that Xenon Pharmaceuticals Inc. (XENE) stock had its last reported insider trading activity 83 days ago on Sep 02. AULIN SHERRY, the Chief Financial Officer of the company, disposed of 15,355 shares for $39.57 on Sep 02. It resulted in a $607,597 divestment by the insider. ROBIN SHERRINGTON sold 43,879 shares at an average price of $38.18 on Sep 01. The insider now owns 16,796 shares following the transaction. On Aug 31, EVP, Strategy & Innovation ROBIN SHERRINGTON sold 21,352 shares at $38.57 apiece. The transaction was valued at $823,547.

Valuation Metrics

The stock’s beta is 1.42. Besides these, the trailing price-to-sales (P/S) ratio of 158.81, the price-to-book (PB) ratio of 2.99.

Financial Health

In the three months ended September 29, Xenon Pharmaceuticals Inc.’s quick ratio stood at 41.80, while its current ratio was 41.80, showing that the company is able to pay off its debt. Based on annual data, XENE earned $97.43 million in gross profit and brought in $18.44 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -14.60%. Return on equity (ROE) for the past 12 months was -16.30%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. XENE’s revenue fell -6146.15% to $0.54 million during the quarter, while net income inched up to $0.13 million. While analysts expected Xenon Pharmaceuticals Inc. to report -$0.52 quarterly earnings, the actual figure was -$0.57 per share, beating the consensus estimate by -9.60%. During the quarter, the company generated -$37.77 million in EBITDA. The liabilities of Xenon Pharmaceuticals Inc. were 22.69 million at the end of its most recent quarter ended September 29, and its total debt was $7.16 million. The value of shareholders’ equity is $62.54 million.

Technical Picture

This quick technical analysis looks at Xenon Pharmaceuticals Inc.’s (XENE) price momentum. With a historical volatility rate of 34.65%, the RSI 9-day stood at 47.21% on 23 November.

With respect to its five-day moving average, the current Xenon Pharmaceuticals Inc. price is up by +3.96% percent or $1.31. At present, XENE shares trade -5.78% below its 20-day simple moving average and +8.77% percent above its 100-day simple moving average. However, the stock is currently trading approximately -11.44% below its SMA50 and +14.49% above its SMA200.

Stochastic coefficient K was 47.08% and Stochastic coefficient D was 40.85%, while ATR was 1.56. Given the Stochastic reading of 50.79% for the 14-day period, the RSI (14) reading has been calculated as 46.38%. As of today, the MACD Oscillator reading stands at 0.20, while the 14-day reading stands at -0.01.


Please enter your comment!
Please enter your name here